From a recent study conducted by researchers queen’s university Three antibiotic therapies used to treat community-acquired pneumonia showed similar efficacy, a Canadian study shows. The findings challenge current recommendations and provide doctors with more flexible treatment options to address this common respiratory disease. The study, which collected data from more than 23,000 patients, provides strong evidence supporting the effectiveness of these antibiotic treatments.
Research features
The study examined data on 23,512 patients admitted to 19 Canadian hospitals between 2015 and 2021. The patients were treated with one of the following antibiotic regimens: a beta-lactam plus a macrolide (what the researchers called the first-line regimen), a beta-lactam alone, a respiratory fluoroquinolone, or a beta-lactam plus a beta-lactam. Doxycycline. The researchers compared all-cause in-hospital mortality and length of stay between treatment groups.
The researchers divided the patients into four groups based on the type of antibiotics they received within 48 hours of admission. A total of 9,340 patients received a beta-lactam plus a macrolide, 9,146 patients received a beta-lactam alone, 4,510 patients received a fluoroquinolone, and 516 patients received a beta-lactam plus a macrolide. Xicycline treatment. The duration of treatment with any antibiotic effective against community-acquired pneumonia is at least four days or until discharge or death.
All-cause in-hospital mortality was the primary criterion assessed and was 7.5%, 9.7%, 6.7%, and 6.0% for each treatment group, respectively. Compared with first-line therapy with a beta-lactam plus a macrolide, the adjusted risk differences for beta-lactam alone, fluoroquinolone, and beta-lactam plus doxycycline were 1.5%, -0.9%, and -1.9, respectively. %.
There were no significant differences in adjusted in-hospital mortality between beta-lactams plus macrolides and fluoroquinolones or beta-lactams plus doxycycline. However, studies have shown that the 1.5% difference observed with beta-lactam alone is small but clinically important.
Key secondary endpoints were length of stay and survival to discharge. The average length of stay was 4.6 days for a beta-lactam plus a macrolide, 5.2 days for a beta-lactam alone, 4.6 days for a fluoroquinolone, and 4.6 days for a beta-lactam alone. The mean length of hospital stay for amide plus doxycycline was 6.0 days.
Patients receiving beta-lactam alone had longer discharge times, suggesting that this treatment regimen may be less effective than other treatment options.Furthermore, patients in the β-lactam group only developed Danger probability The subdistribution of discharges relative to the group receiving beta-lactam plus macrolide was 0.90 after adjustment with propensity score and overlap weights.
Key results of antibiotic treatment regimens
All-cause in-hospital mortality was similar among the four treatment groups and the differences were minimal and not statistically significant. The mean length of stay was also similar among the treatment groups, but patients who received only beta-lactam therapy had longer stays. These results suggest that alternative antibiotic therapies are equally effective in treating nonsevere community-acquired pneumonia.
These findings have important implications for current clinical practice and treatment guidelines. The results support beta-lactam inhibition as a first-line treatment option only, as recommended in the guidelines. American Thoracic Society (amphetamine-type stimulants) and Infectious Diseases Society of America (IDSA). Instead, a beta-lactam plus macrolide, a respiratory fluoroquinolone, or a beta-lactam plus doxycycline is recommended as equally effective treatment options. Physicians can tailor antibiotic treatment options based on individual patient characteristics, such as allergies, risk of secondary infection, or drug interactions.
This study provides strong evidence that three antibiotic therapies used to treat community-acquired pneumonia show similar efficacy. These results support revisions to current treatment guidelines and provide clinicians with more flexible options to address this common respiratory disease. Although further research is needed to confirm these findings, this study represents an important advance in the field of community-acquired pneumonia and has the potential to improve clinical outcomes for affected patients. Physicians can use this information to make informed, personalized decisions about the treatment of community-acquired pneumonia based on each patient’s individual needs.